Chemotherapy alone for organ preservation in advanced laryngeal cancer
Vasu Divi(University of Michigan), Gregory T. Wolf(University of Michigan), Mark E. Prince(University of Michigan), Carol R. Bradford(The Ohio State University), Jeffrey S. Moyer(Environmental Protection Agency), Julia S. Lee(University of Michigan), Christina Tsien(McGill University Health Centre), Norman D. Hogikyan(Michigan Medicine), Susan G. Urba(University of Michigan), Douglas B. Chepeha(University of Michigan), Francis P. Worden(Georgetown University), Theodoros N. Teknos(University Hospitals Seidman Cancer Center), Avraham Eisbruch(University of Michigan–Ann Arbor)
Cited by 20
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Validation of an instrument to measure voice-related quality of life (V-RQOL)
|Journal of Voice|1999|1.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653